Imatinib and Trametinib for KRAS-mutated solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have an advanced solid tumor with a KRAS G12X mutation that has gotten worse during or within 6 months of standard chemotherapy, or no standard therapy exists.
- Your tumor can be measured on scans (using RECIST criteria).
- You are able to perform daily activities with some help (ECOG score 0-2) and have a life expectancy of at least 8 weeks.
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
- You have not had an allergic reaction to imatinib or trametinib, and you are not currently taking other kinase inhibitors or strong interacting medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.